Dendritic cell antigen presentation of melanoma-associated antigens

Dendritic cells are the primary antigen-presenting cells responsible for activating the adaptive immune system by presenting melanoma-associated antigens to T lymphocytes. They capture, process, and present these antigens via major histocompatibility complex (MHC) molecules to naive CD4+ and CD8+ T cells, leading to the generation of cytotoxic T cell responses against melanoma cells. This process, termed cross-presentation, is essential for the success of melanoma immunotherapy and underlies the mechanism of action for dendritic cell vaccines. However, in the tumor microenvironment, dendritic cell function can be suppressed, reducing the efficacy of immune-mediated tumor eradication. Thus, therapeutic strategies often aim to enhance DC antigen presentation capacity and improve antitumor T cell activation while overcoming tumor-induced immunosuppression.

Other names

Dendritic cell-mediated antigen presentation in melanomaDC activation against melanoma antigensAntigen-presenting dendritic cells (in melanoma context)Tumor antigen cross-presentation by dendritic cells

Presentation of melanoma-associated antigens via MHC class I and II to naive T cells, resulting in the activation of cytotoxic CD8+ and helper CD4+ T cells Cross-priming: DCs process exogenous tumor antigens and cross-present them to CD8+ T cells for the initiation of antitumor responses Maturation of DCs enhances antigen presentation and T cell activation Regulation by costimulatory and coinhibitory molecules (CD80/86, CD28, CTLA-4)